COPENHAGEN, Denmark, April 25, 2024 (Globe Newswire) — Ascendis Pharma A/S (Nasdaq: ASND) today reported its first quarter 2024 financial results, Thursday, May 2, 2024. The company announced it would provide a business update after the transaction closes. About the US financial market. Ascendis Pharma will also host a conference call and live webcast on May 2, 2024 at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2024 financial results.
If you would like to attend, please access the live webcast here or pre-register for the conference call here. A link to the live webcast is also available on the “Investors and News'' section of the Ascendis Pharma website (https://investors.ascendispharma.com). A replay of the webcast will be available for viewing on this section of the Ascendis Pharma website immediately following the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making meaningful changes in patients' lives. Guided by our core values of patients, science, and passion, Ascendis uses TransCon technology to develop potentially best-in-class new treatments. Ascendis is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States. For more information, please visit ascendispharma.com.
Forward-looking statements
This press release contains forward-looking statements that involve significant risks and uncertainties. All statements, other than statements of historical fact, contained in this press release regarding Ascendis' future business, plans and operating objectives are forward-looking statements. Examples of such statements include (i) Ascendis' ability to apply its TransCon technology platform to build a leading, fully integrated biopharmaceutical company; and (ii) Ascendis' ability to apply his TransCon technology to A new and potentially best-in-class treatment. Ascendis may not actually achieve its plans, carry out its intentions, or meet its expectations or projections disclosed in such forward-looking statements, and therefore Ascendis may not place undue reliance on these forward-looking statements. You shouldn't. Actual results or events may differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. A number of important factors could cause actual results or events to differ materially from Ascendis' forward-looking statements, including: unanticipated safety or efficacy issues affecting Ascendis' development programs or commercially available products; unanticipated expenses related to the commercialization of approved Ascendis products; unanticipated expenses related to Ascendis' development programs; unanticipated selling, general and administrative expenses, other research and development expenses, and Ascendis' operations generally; delays in program development related to manufacturing, regulatory requirements, speed of patient recruitment or other unanticipated delays; Ascendis' ability to obtain additional capital, if necessary, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors; For more information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements and risks associated with Ascendis' business generally, please refer to our Form 20- filed in the United States. See Ascendis Annual Report by F. Ascendis' other future reports filed with or filed with the Securities and Exchange Commission (SEC) on February 7, 2024; Forward-looking statements do not reflect the potential effects of any future licenses, partnerships, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis undertakes no obligation to update forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma Group. © April 2024 Ascendis Pharma A/S.
